Halozyme stock rises after winning injunction against Merck

Halozyme shares rose 2% after a Dutch court found Merck infringed Halozyme’s EP 2,797,622 patent and ordered MSD BV to halt specified Keytruda SC activities in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The court rejected Merck’s challenge to the patent’s validity; patients can still receive Keytruda’s IV formulation, which is outside the injunction. Halozyme also cited a preliminary injunction in Germany and a U.S. lawsuit alleging infringement of 15 patents.

Analysis

The ruling’s larger potential value to Halozyme is bargaining leverage, not simply blocked European sales: a validated infringement finding could improve its position in licensing negotiations and influence how other customers assess exposure to the same patent. That benefit is conditional, however; this is a country-specific injunction, not a final global determination, and appeal, a stay, or a design-around could reduce its force. Do not extrapolate it to Halozyme’s entire technology portfolio.

For Merck, the near-term commercial hit may be contained because the IV option remains available; the more meaningful risk is delayed conversion to a more convenient formulation in affected markets, plus uncertainty around the separate U.S. QLEX case. The European injunction does not decide that case. The event is therefore more consequential to Halozyme’s licensing leverage than to Merck’s consolidated economics, absent evidence that SC adoption was expected to be material.

Near term, watch for an appeal or stay and any change in launch plans. Over 1–3 months, procedural developments and Merck’s response will determine whether the injunction holds practical force; over 6–18 months, the U.S. litigation could matter more to valuation. Contrarian read: the share move may underprice the value of a favorable precedent, but may also overstate earnings impact before royalty exposure, affected-market sales, and appeal risk are quantified.

Key Decisions for Investors

• HALO: Treat as a positive but litigation-contingent catalyst, not a proven earnings upgrade. Consider only a modest, staged long on weakness; avoid chasing the initial move until the injunction’s enforceability and Halozyme’s economic exposure are clearer.
• Do not short MRK solely on this ruling. IV substitution limits the immediate access shock, and the article provides no evidence that affected-market SC sales would materially change Merck’s consolidated outlook.
• Track the appeal/stay docket, any change in European launch plans, and company disclosures on affected-market sales or licensing economics. A stay, reversal, or evidence that IV use absorbs most demand would weaken the HALO thesis.
• Keep the U.S. QLEX case as a separate catalyst: verify claim scope, procedural milestones, and any ruling before assigning value to a U.S. commercial restriction. A U.S. adverse ruling for Halozyme would materially challenge the broader leverage thesis.